{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:09:20Z","timestamp":1648832960536},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmaceutical Association (1996)"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1331\/108658003321480812","type":"journal-article","created":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T16:53:18Z","timestamp":1055868798000},"page":"327-328","source":"Crossref","is-referenced-by-count":4,"title":["New Antibody Approved for Treatment of Rheumatoid Arthritis"],"prefix":"10.1016","volume":"43","author":[{"given":"Peggy","family":"Piascik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1331\/108658003321480812_bb0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","volume":"46","year":"2002","journal-title":"Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum."},{"key":"10.1331\/108658003321480812_bb0015","unstructured":"American College of Rheumatology.Rheumatoid Arthritis[publication online]. Atlanta,Ga: American College ofRheumatology; 2000. Availableat: www.rheumatology.org\/patients\/factsheet\/ra.html.Accessed January 7, 2003"},{"key":"10.1331\/108658003321480812_bb0020","doi-asserted-by":"crossref","unstructured":"Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001:344:907\u201316.","DOI":"10.1056\/NEJM200103223441207"},{"key":"10.1331\/108658003321480812_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1331\/108658003321480812_bb0030","year":"2003"},{"key":"10.1331\/108658003321480812_bb0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1331\/108658003321480812_bb0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1331\/108658003321480812_bb0045","article-title":"The Health Assessment Questionnaire 1995-status and review. In: ad Quality of Life and Pharmacoeconomics in Clinical Trials.2nd ed.","author":"Ramey","year":"1996"},{"key":"10.1331\/108658003321480812_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol."},{"key":"10.1331\/108658003321480812_bb0055","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.","volume":"29","author":"den Broeder","year":"2002","journal-title":"J Rheum."},{"key":"10.1331\/108658003321480812_bb0060","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk.","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer."},{"key":"10.1331\/108658003321480812_bb0065","unstructured":"Abbott Laboratories suppliesnewly approved rheumatoidarthritis (RA) mediationHumira (adalimumab) to U.S.pharmacies this week [pressrelease]. January 6, 2003.Available at: www.humira.com. Accessed February 6,2003."},{"key":"10.1331\/108658003321480812_bb0070","unstructured":"Humira Web site. Available at:www.humira.com. AccessedFebruary 6, 2003."}],"container-title":["Journal of the American Pharmaceutical Association (1996)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215300176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215300176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T21:16:50Z","timestamp":1584825410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1086580215300176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S1086580215300176"],"URL":"https:\/\/doi.org\/10.1331\/108658003321480812","relation":{},"ISSN":["1086-5802"],"issn-type":[{"value":"1086-5802","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}